查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081448

眼科疾病治療市場：2026-2032年全球市場預測（依藥物類別、給藥途徑、劑型、藥物類型、適應症、通路和最終用戶分類）

Optical Disorders Drugs Market by Drug Class, Route Of Administration, Dosage Form, Drug Type, Indication, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，眼科疾病治療市場將成長至 760.2 億美元，複合年成長率為 10.16%。

主要市場統計數據
基準年 2025 385.9億美元
預計年份：2026年 424.6億美元
預測年份 2032 760.2億美元
複合年成長率 (%) 10.16%

隨著人口老化、糖尿病盛行率上升、螢幕使用過多的生活方式以及診斷手段的普及，眼科治療市場正在擴張，因為人們對青光眼、乾眼症、視網膜疾病、眼部發炎、感染疾病和罕見眼科疾病的治療需求不斷成長。

世界衛生組織（世衛組織）的數據顯示，至少有22億人因近視或遠視而患有視力障礙，其中至少10億人是可以預防的或尚未得到充分治療。這導致人們對實證眼科藥物的需求持續成長，這些藥物包括抗血管內皮生長因子（VEGF）藥物、前列腺素類似物、皮質類固醇、抗生素、免疫調節劑、補體抑制劑以及新型基因和細胞療法。

眼科藥物領域的變革性變化

市場正從控制慢性症狀轉向早期診斷、長效治療、精準醫療和緩解疾病。視網膜疾病的治療正在被重新定義，包括持續抗VEGF療法、雙特異性機制以及針對地圖狀萎縮的補體抑制；而青光眼的治療則朝著固定劑量組合藥物、緩釋製劑以及提高用藥依從性的方案發展。

人工智慧（AI）的累積影響

人工智慧 (AI) 正累積眼科疾病的藥物研發和商業化，其途徑包括改進基於影像的篩檢、患者識別、臨床試驗招募、病變量化和治療反應監測。一項獲得 FDA 批准的用於糖尿病視網膜病變篩檢的自主人工智慧系統已證實了演算法驅動型眼科診療的臨床有效性。

全球眼科市場的關鍵區域洞察

亞太地區是重點關注區域，因為該地區患者群體龐大、都市化進程迅速、東亞近視患病率高、糖尿病負擔日益加重，且私人眼科網路不斷擴張。儘管中國、印度、日本、韓國、澳洲和東協市場對視網膜疾病、青光眼、乾眼症、眼部過敏和感染疾病的治療需求不斷成長，但在保險覆蓋範圍、農村地區專科醫生的可及性以及價格承受能力方面，區域間仍然存在差異。

針對特定群體的關鍵洞察，以進行策略市場優先排序

東協地區的需求正在成長。這主要得益於新加坡、馬來西亞、泰國、印尼、越南和菲律賓等國透過公私合營拓展眼科醫療服務，以應對糖尿病視網膜病變、青光眼、乾眼症、眼部感染疾病和白內障等併發症。在海灣合作理事會（GCC）國家，專業的醫療基礎設施、高階品牌治療和糖尿病相關的視力保護是重點，其中沙烏地阿拉伯和阿拉伯聯合大公國（阿拉伯聯合大公國）已成為先進眼科醫療的重要中心。

各國對眼科疾病治療需求的關鍵洞察

美國在新眼科藥物的上市、視網膜生物製藥的應用、臨床試驗、專科醫療的商業化以及患者支持基礎設施方面處於主導地位。而加拿大則著重於保險報銷和各省之間公平的醫療服務取得。墨西哥和巴西是拉丁美洲的重要市場，這兩個國家私人眼科醫療的發展伴隨著公共部門成本效益的限制以及視網膜專科醫生資源分配不均的問題。英國、德國、法國、義大利和西班牙仍然是歐洲的核心市場，其中德國通常支持早期准入，英國高度重視醫療技術評估，法國專注於臨床療效評估，而義大利和西班牙則負責管理區域報銷和採購趨勢。

為行業領導者提供的實用建議

產業領導者應優先考慮差異化的臨床價值，尤其要關注藥物的持續性、安全性、依從性、降低處方負擔以及可衡量的視覺功能結果。相關策略應包括：收集更廣泛的真實世界證據、進行病患支援計畫、加強醫師教育，以及開發可供保險公司使用的抗VEGF療法、青光眼藥物、乾眼症藥物、抗發炎藥物、抗感染藥、補體抑制劑和罕見眼科疾病治療藥物的價值評估資料。

調查方法和證據標準

本執行摘要基於公共衛生機構、監管機構、同行評審的眼科文獻、臨床試驗註冊庫、衛生技術評估 (HTA) 文件、治療指南和醫療基礎設施指標的二手研究。資訊來源包括世界衛生組織視覺健康數據、主要組織的監管活動、國家篩檢政策以及已發表的青光眼、糖尿病視網膜病變、老齡化黃斑部病變、乾眼症和遺傳性視網膜疾病的疾病負擔證據。

結論與策略展望

受全球對有效眼科療法需求不斷成長的推動，眼科治療市場預計將持續成長。這種需求成長的促進因素包括視力障礙、糖尿病、人口老化以及數位生活方式的普及。視網膜疾病、青光眼、乾眼症、眼部發炎、感染性眼科疾病和罕見遺傳性視網膜疾病等領域的創新最為活躍。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：眼科疾病治療市場：依藥物類別分類

  • α受體促效劑
  • 抗 VEGF 藥物
    • 阿柏西普
    • Bevacizumab
    • 布羅盧西珠單抗
    • 法利西單抗
    • 雷尼珠單抗
  • BETA阻斷劑
  • 碳酸酐酶抑制劑
  • 皮質類固醇
  • 前列腺素類似物

第8章：眼科疾病治療藥物市場：依給藥途徑分類

  • 玻璃體內注射
  • 眼眶周圍注射
  • 結膜下注射
  • 外用

第9章：眼科疾病治療藥物市場：依劑型分類

  • 解決方案
  • 懸浮液
  • 藥片

第10章：眼科疾病治療藥物市場：依藥物類型分類

  • 品牌
  • 非專利的

第11章：眼科疾病治療市場：依適應症分類

  • 老齡化黃斑部病變
  • 結膜炎
  • 糖尿病黃斑部水腫
  • 青光眼
  • 葡萄膜炎

第12章：眼科疾病治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：眼科疾病治療市場：依最終使用者分類

  • 門診手術中心
  • 醫院
  • 眼科診所

第14章：眼科疾病治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章：眼科疾病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：眼科疾病治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • AbbVie Inc.
  • Adverum Biotechnologies, Inc.
  • Aerie Pharmaceuticals, Inc.
  • Ajanta Pharma Ltd.
  • Alcon Inc.
  • Bausch+Lomb Corporation
  • Bayer AG
  • Beximco Pharmaceuticals Ltd.
  • Carl Zeiss AG
  • Chengdu Kanghong Pharmaceutical Group Co., Ltd.
  • Cipla Limited
  • Ellex Medical Lasers Ltd.
  • Essilor International SA
  • EyeGate Pharmaceuticals, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd
  • Glaukos Corporation
  • Hoya Corporation
  • ICON plc
  • Intas Pharmaceuticals Ltd.
  • Iridex Corporation
  • Johnson & Johnson Service, Inc.
  • Kalvista Pharmaceuticals Inc.
  • Lotus Pharmaceuticals
  • Lupin Limited
  • Merck & Co., Inc.
  • Nicox SA
  • Novartis AG
  • Ocular Therapeutix, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Outlook Therapeutics, Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Senju Pharmaceutical Co.,Ltd.
  • Somerset Pharma, LLC.
  • Sun Pharmaceutical Industries Ltd.
Product Code: MRR-434CCDA05224

The Optical Disorders Drugs Market is projected to grow by USD 76.02 billion at a CAGR of 10.16% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 38.59 billion
Estimated Year [2026] USD 42.46 billion
Forecast Year [2032] USD 76.02 billion
CAGR (%) 10.16%

The optical disorders drugs market is expanding as aging populations, diabetes prevalence, screen-intensive lifestyles, and broader diagnostic access increase demand for therapies for glaucoma, dry eye disease, retinal disorders, ocular inflammation, infections, and rare ophthalmic conditions.

The World Health Organization reports that at least 2.2 billion people live with near or distance vision impairment, with at least 1 billion cases considered preventable or not yet addressed. This creates a durable need for evidence-based ophthalmic pharmaceuticals, including anti-VEGF agents, prostaglandin analogs, corticosteroids, antibiotics, immunomodulators, complement inhibitors, and emerging gene and cell therapies.

Transformative Shifts in the Ophthalmic Drug Landscape

The market is shifting from chronic symptom control toward earlier diagnosis, longer-acting therapy, precision medicine, and disease modification. Retina care is being reshaped by durable anti-VEGF regimens, bispecific mechanisms, and complement inhibition for geographic atrophy, while glaucoma management is moving toward fixed-dose combinations, sustained-release delivery, and adherence-friendly options.

Payers and providers are also prioritizing real-world outcomes, treatment durability, and total cost of care. This favors manufacturers that can demonstrate reduced injection burden, better persistence, improved safety, and measurable patient quality-of-life benefits across ophthalmology care pathways.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is cumulatively changing optical disorder drug development and commercialization by improving image-based screening, patient identification, clinical trial recruitment, lesion quantification, and treatment-response monitoring. FDA-authorized autonomous AI for diabetic retinopathy screening has validated the clinical relevance of algorithm-enabled eye care.

For drug developers, AI can support OCT and fundus image analysis, biomarker discovery, synthetic control exploration, pharmacovigilance signal detection, and territory planning. The greatest value will come from regulated, explainable, privacy-preserving AI integrated with ophthalmologists, optometrists, primary care, and specialty pharmacy networks.

Key Regional Insights Across Global Ophthalmology Markets

Asia-Pacific is a high-priority region due to large patient pools, rapid urbanization, high myopia prevalence in East Asia, increasing diabetes burden, and expanding private ophthalmology networks. China, India, Japan, South Korea, Australia, and ASEAN markets are strengthening demand for retinal, glaucoma, dry eye, ocular allergy, and infection therapies, although reimbursement depth, rural specialist access, and affordability remain uneven.

North America remains a leading innovation and commercialization hub, supported by established regulatory pathways, advanced retina practices, specialty pharmacy infrastructure, clinical trial density, and rapid adoption of novel biologics. Europe benefits from universal health systems, strong ophthalmology research, pharmacovigilance rigor, and structured health technology assessment, while Latin America shows rising access through private care, public screening programs, and growing treatment of diabetic eye disease. The Middle East is investing in specialty hospitals, diabetes care, and premium ophthalmology services, and Africa represents a long-term access opportunity where affordability, supply continuity, trained eye care personnel, and screening capacity are decisive.

Key Group Insights for Strategic Market Prioritization

ASEAN demand is rising as Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines expand eye care services and address diabetic retinopathy, glaucoma, dry eye, ocular infections, and cataract-related comorbidities through mixed public-private systems. The GCC is prioritizing specialty care infrastructure, premium branded therapies, and diabetes-related vision protection, with Saudi Arabia and the United Arab Emirates serving as important access hubs for advanced ophthalmology treatment.

The European Union emphasizes health technology assessment evidence, pharmacovigilance, biosimilar readiness, cross-border regulatory consistency, and equitable access across member states. BRICS markets combine substantial patient volume with pricing pressure, procurement complexity, domestic manufacturing priorities, and localization expectations. G7 countries set innovation benchmarks through advanced regulation, clinical adoption, and reimbursement scrutiny, while NATO markets overlap significantly with high-income systems that value supply resilience for essential medicines, biologics, anti-infectives, and sterile ophthalmic formulations.

Key Country Insights in Optical Disorders Drug Demand

The United States leads in ophthalmic drug launches, retina biologic utilization, clinical trials, specialty commercialization, and patient support infrastructure, while Canada emphasizes reimbursement evidence and equitable provincial access. Mexico and Brazil are important Latin American markets where private ophthalmology growth coexists with public-sector affordability constraints and uneven access to retina specialists. The United Kingdom, Germany, France, Italy, and Spain remain core European markets, with Germany often supporting early access, the United Kingdom placing strong emphasis on health technology assessment, France focusing on clinical benefit evaluation, and Italy and Spain managing regional reimbursement and procurement dynamics.

Russia requires careful navigation of localization, procurement, and supply continuity dynamics. China offers scale across myopia, diabetic eye disease, glaucoma, dry eye, and retinal disorders, while India combines very high unmet need with cost-sensitive access, growing domestic manufacturing, and expanding ophthalmology hospital networks. Japan has strong demand linked to aging and retinal disease, Australia benefits from mature reimbursement and screening programs, and South Korea combines advanced digital health infrastructure with high specialist density, strong diagnostic adoption, and active interest in AI-enabled eye care.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated clinical value, especially durability, safety, adherence, reduced administration burden, and measurable visual function outcomes. Strategies should include broader real-world evidence generation, patient support programs, physician education, and payer-ready value dossiers for anti-VEGF therapies, glaucoma drugs, dry eye treatments, anti-inflammatory agents, anti-infectives, complement inhibitors, and rare eye disease therapies.

Companies should also diversify supply chains, prepare for biosimilar and generic competition, strengthen sterile manufacturing reliability, and pursue partnerships with diagnostic platforms, AI imaging developers, and specialty eye care networks. Access strategies must be localized by reimbursement maturity, public-private mix, pricing sensitivity, regulatory requirements, and specialist availability.

Research Methodology and Evidence Standards

This executive summary is built on secondary research from public health agencies, regulatory bodies, peer-reviewed ophthalmology literature, clinical trial registries, HTA documents, treatment guidelines, and healthcare infrastructure indicators. Sources considered include WHO vision health data, regulatory activity from major agencies, national screening policies, and published disease-burden evidence for glaucoma, diabetic retinopathy, age-related macular degeneration, dry eye disease, and inherited retinal disorders.

The analysis triangulates epidemiology, treatment guidelines, approval trends, pricing and reimbursement conditions, regional access patterns, and competitive dynamics. Insights are synthesized to support strategic planning, not to replace primary market research, medical advice, product-specific regulatory assessment, or country-specific market access consultation.

Conclusion and Strategic Outlook

The optical disorders drugs market is positioned for sustained growth as global vision impairment, diabetes, aging, and digital lifestyle exposure increase the need for effective ophthalmic therapies. Innovation is strongest in retina, glaucoma, dry eye disease, ocular inflammation, infectious eye disease, and rare inherited retinal disorders.

Organizations that combine clinically meaningful differentiation with AI-enabled evidence, region-specific access planning, and resilient supply will be best positioned. The next phase of competition will reward therapies that improve outcomes while reducing treatment burden, supporting adherence, and lowering system-level costs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Optical Disorders Drugs Market, by Drug Class

  • 7.1. Alpha Agonists
  • 7.2. Anti-Vegf Agents
    • 7.2.1. Aflibercept
    • 7.2.2. Bevacizumab
    • 7.2.3. Brolucizumab
    • 7.2.4. Faricimab
    • 7.2.5. Ranibizumab
  • 7.3. Beta Blockers
  • 7.4. Carbonic Anhydrase Inhibitors
  • 7.5. Corticosteroids
  • 7.6. Prostaglandin Analogs

8. Optical Disorders Drugs Market, by Route Of Administration

  • 8.1. Intravitreal Injection
  • 8.2. Periocular Injection
  • 8.3. Subconjunctival Injection
  • 8.4. Topical

9. Optical Disorders Drugs Market, by Dosage Form

  • 9.1. Solution
  • 9.2. Suspension
  • 9.3. Tablets

10. Optical Disorders Drugs Market, by Drug Type

  • 10.1. Branded
  • 10.2. Generic

11. Optical Disorders Drugs Market, by Indication

  • 11.1. Age-Related Macular Degeneration
  • 11.2. Conjunctivitis
  • 11.3. Diabetic Macular Edema
  • 11.4. Glaucoma
  • 11.5. Uveitis

12. Optical Disorders Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Optical Disorders Drugs Market, by End User

  • 13.1. Ambulatory Surgical Centers
  • 13.2. Hospitals
  • 13.3. Ophthalmology Clinics

14. Optical Disorders Drugs Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Optical Disorders Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Optical Disorders Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. AbbVie Inc.
  • 18.2. Adverum Biotechnologies, Inc.
  • 18.3. Aerie Pharmaceuticals, Inc.
  • 18.4. Ajanta Pharma Ltd.
  • 18.5. Alcon Inc.
  • 18.6. Bausch + Lomb Corporation
  • 18.7. Bayer AG
  • 18.8. Beximco Pharmaceuticals Ltd.
  • 18.9. Carl Zeiss AG
  • 18.10. Chengdu Kanghong Pharmaceutical Group Co., Ltd.
  • 18.11. Cipla Limited
  • 18.12. Ellex Medical Lasers Ltd.
  • 18.13. Essilor International S.A.
  • 18.14. EyeGate Pharmaceuticals, Inc.
  • 18.15. EyePoint Pharmaceuticals, Inc.
  • 18.16. F. Hoffmann-La Roche Ltd
  • 18.17. Glaukos Corporation
  • 18.18. Hoya Corporation
  • 18.19. ICON plc
  • 18.20. Intas Pharmaceuticals Ltd.
  • 18.21. Iridex Corporation
  • 18.22. Johnson & Johnson Service, Inc.
  • 18.23. Kalvista Pharmaceuticals Inc.
  • 18.24. Lotus Pharmaceuticals
  • 18.25. Lupin Limited
  • 18.26. Merck & Co., Inc.
  • 18.27. Nicox S.A.
  • 18.28. Novartis AG
  • 18.29. Ocular Therapeutix, Inc.
  • 18.30. Otsuka Pharmaceutical Co., Ltd.
  • 18.31. Outlook Therapeutics, Inc.
  • 18.32. Pfizer Inc.
  • 18.33. Regeneron Pharmaceuticals, Inc.
  • 18.34. Santen Pharmaceutical Co., Ltd.
  • 18.35. Senju Pharmaceutical Co.,Ltd.
  • 18.36. Somerset Pharma, LLC.
  • 18.37. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OPTICAL DISORDERS DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL OPTICAL DISORDERS DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL OPTICAL DISORDERS DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL OPTICAL DISORDERS DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL OPTICAL DISORDERS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL OPTICAL DISORDERS DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ALPHA AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ALPHA AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ALPHA AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-VEGF AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-VEGF AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-VEGF AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AFLIBERCEPT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AFLIBERCEPT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AFLIBERCEPT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BEVACIZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BEVACIZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BEVACIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BROLUCIZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BROLUCIZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BROLUCIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FARICIMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FARICIMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FARICIMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RANIBIZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RANIBIZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RANIBIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BETA BLOCKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BETA BLOCKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARBONIC ANHYDRASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARBONIC ANHYDRASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARBONIC ANHYDRASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROSTAGLANDIN ANALOGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PROSTAGLANDIN ANALOGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PROSTAGLANDIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRAVITREAL INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INTRAVITREAL INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRAVITREAL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PERIOCULAR INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PERIOCULAR INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PERIOCULAR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SUBCONJUNCTIVAL INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SUBCONJUNCTIVAL INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SUBCONJUNCTIVAL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SOLUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SOLUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SOLUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SUSPENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SUSPENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SUSPENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRANDED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENERIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CONJUNCTIVITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CONJUNCTIVITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CONJUNCTIVITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIABETIC MACULAR EDEMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DIABETIC MACULAR EDEMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DIABETIC MACULAR EDEMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GLAUCOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GLAUCOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GLAUCOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL UVEITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL UVEITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL UVEITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL OPHTHALMOLOGY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL OPHTHALMOLOGY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL OPHTHALMOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. GCC OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. GCC OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 169. GCC OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 170. GCC OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. GCC OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 172. GCC OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. GCC OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 174. GCC OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. GCC OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. G7 OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. G7 OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 196. G7 OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 197. G7 OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. G7 OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 199. G7 OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. G7 OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 201. G7 OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. G7 OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. NATO OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. NATO OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 205. NATO OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 206. NATO OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. NATO OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 208. NATO OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. NATO OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 210. NATO OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. NATO OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. CANADA OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. CANADA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 224. CANADA OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 225. CANADA OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. CANADA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 227. CANADA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. CANADA OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 229. CANADA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. CANADA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. MEXICO OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 232. MEXICO OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 233. MEXICO OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 234. MEXICO OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. MEXICO OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 236. MEXICO OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. MEXICO OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 238. MEXICO OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. MEXICO OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. BRAZIL OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. BRAZIL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 242. BRAZIL OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 243. BRAZIL OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. BRAZIL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 245. BRAZIL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. BRAZIL OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 247. BRAZIL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. BRAZIL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED KINGDOM OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED KINGDOM OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED KINGDOM OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED KINGDOM OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED KINGDOM OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED KINGDOM OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED KINGDOM OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. GERMANY OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 259. GERMANY OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 260. GERMANY OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 261. GERMANY OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. GERMANY OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 263. GERMANY OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. GERMANY OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 265. GERMANY OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 266. GERMANY OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. FRANCE OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. FRANCE OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 269. FRANCE OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 270. FRANCE OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 271. FRANCE OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 272. FRANCE OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. FRANCE OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 274. FRANCE OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 275. FRANCE OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. RUSSIA OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 277. RUSSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 278. RUSSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 279. RUSSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. RUSSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 281. RUSSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. RUSSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 283. RUSSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 284. RUSSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. ITALY OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 286. ITALY OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 287. ITALY OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 288. ITALY OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 289. ITALY OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 290. ITALY OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. ITALY OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 292. ITALY OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 293. ITALY OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. SPAIN OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 295. SPAIN OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 296. SPAIN OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 297. SPAIN OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 298. SPAIN OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 299. SPAIN OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. SPAIN OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 301. SPAIN OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 302. SPAIN OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 312. INDIA OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 313. INDIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 314. INDIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 315. INDIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 316. INDIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 317. INDIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. INDIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 319. INDIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 320. INDIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. JAPAN OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 322. JAPAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 323. JAPAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 324. JAPAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 325. JAPAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 326. JAPAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. JAPAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 328. JAPAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 329. JAPAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 330. AUSTRALIA OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 331. AUSTRALIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 332. AUSTRALIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 333. AUSTRALIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 334. AUSTRALIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 335. AUSTRALIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 336. AUSTRALIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 337. AUSTRALIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 338. AUSTRALIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 339. SOUTH KOREA OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 340. SOUTH KOREA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 341. SOUTH KOREA OPTICAL DISORDERS DRUGS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 342. SOUTH KOREA OPTICAL DISORDERS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 343. SOUTH KOREA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 344. SOUTH KOREA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 345. SOUTH KOREA OPTICAL DISORDERS DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 346. SOUTH KOREA OPTICAL DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 347. SOUTH KOREA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)